neparvis
novartis europharm limited - sacubitril, valsartan - südamepuudulikkus - reniini-angiotensiini süsteemi toimivad ained - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.
isoprenalina cloridrato s.a.l.f. süstelahus
s.a.l.f. s.p.a. laboratorio farmacologico - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk
isoprenalin inj süstelahus
ifet s.a. (ex elviony s.a.) - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk
isoprenalina cloridr süstelahus
monico spa - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk
isoprenalina cloridrato monico süstelahus
monico spa - isoprenaliin - süstelahus - 0,2mg 1ml 1ml 5tk
lumigan
abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - suurenenud silmasisese rõhu langus kroonilise avatud nurga glaukoomi ja silma hüpertensioonina (monoteraapiana või beeta-adrenoblokaatorite täiendava ravina).
torisel
pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastilised ained - neeru-cell carcinomatorisel on näidustatud esimese rea ravi täiskasvanud patsientidel, kellel on arenenud neeru-raku kartsinoomi (rcc), kellel on vähemalt kolm kuuest prognostic riskitegurid. mantlit-cell lymphomatorisel on näidustatud ravi täiskasvanud patsientidel, kellel on taastekkinud ja / või tulekindlad mantlit-raku lümfoom (mcl).
sunitinib accord
accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
norepinephrine kabi infusioonilahuse kontsentraat
fresenius kabi polska sp. z o.o. - norepinefriin (noradrenaliin) - infusioonilahuse kontsentraat - 1mg 1ml 8ml 10tk; 1mg 1ml 5ml 5tk; 1mg 1ml 4ml 10tk; 1mg 1ml 4ml 5tk; 1mg 1ml 5ml 10tk
kisplyx
eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.